Yu Y, Wang L, Zhu X, Liu YF, Ma HY. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction. World J Diabetes 2021; 12(12): 2096-2106 [PMID: 35047123 DOI: 10.4239/wjd.v12.i12.2096]
Corresponding Author of This Article
Hai-Ying Ma, MHSc, Chief Pharmacist, Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Road, Huanggu District, Shenyang 110032, Liaoning Province, China. mhy2021888@163.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Dec 15, 2021; 12(12): 2096-2106 Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2096
Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction
You Yu, Lin Wang, Xu Zhu, Ya-Fei Liu, Hai-Ying Ma
You Yu, Lin Wang, Xu Zhu, Ya-Fei Liu, Hai-Ying Ma, Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China
Author contributions: Yu Y and Ma HY designed the research study; Wang L and Yu Y performed the research; Zhu X, Liu YF and Ma HY analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by The Fourth Affiliated Hospital of China Medical University Institutional Review Board.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Ying Ma, MHSc, Chief Pharmacist, Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Road, Huanggu District, Shenyang 110032, Liaoning Province, China. mhy2021888@163.com
Received: September 2, 2021 Peer-review started: September 2, 2021 First decision: October 3, 2021 Revised: October 15, 2021 Accepted: December 10, 2021 Article in press: December 10, 2021 Published online: December 15, 2021
ARTICLE HIGHLIGHTS
Research background
Type 2 diabetes is a common metabolic disease that is often complicated by abnormal lipid metabolism.
Research motivation
As an antiplatelet drug and thromboxane A inhibitor, sodium ozagrel is widely used to treat ischemic cerebrovascular diseases.
Research objectives
We want to observe the effects of sodium ozagrel combined with atorvastatin on high-mobility group protein B1 (HMGB1) and high-sensitivity-C reactive protein (hs-CRP) in patients with type 2 diabetes mellitus and lacunar infarction.
Research methods
Eighty-two patients with type 2 diabetes mellitus and lacunar infarction treated were categorized into two groups according to the method of treatment (41 patients in each group).
Research results
After treatment, the blood glucose indexes; blood lipid indexes; inflammatory factors; HMGB1, paraoxonase-1, and macrophage migration inhibitory factor levels; erythrocyte sedimentation rate; platelet aggregation rate; and plasma viscosity of the observation group were better than those of the control group.
Research conclusions
Sodium ozagrel with atorvastatin can reduce inflammatory reactions.
Research perspectives
The results need to be verified with further larger scale studies and include other statins in combination with ozagrel.
